Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast02
2023-509260-25-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in triple-negative breast cancer (TNBC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Planned start Jul 2022; status: authorised.
02
Drugs
datopotamab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-509260-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509260-25-00.